Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines

Clinical and Vaccine Immunology

Volumn 18, Issue 2, 2011, Pages 327-336

  Poolman, Jan ^a   Frasch, Carl ^b   Nurkka, Anu ^c   Käyhty, Helena ^c   Biemans, Ralph ^a   Schuerman, Lode ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b Frasch Biologics Consulting   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; STREPTOCOCCUS PNEUMONIAE 19F POLYSACCHARIDE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL IMMUNITY; CHILD; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; CYANYLATION CONJUGATION; DRUG CONJUGATION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; NORMAL HUMAN; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCTIVE AMINATION; STREPTOCOCCACEAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PNEUMONIAE 19A; STREPTOCOCCUS PNEUMONIAE 19F; VACCINATION;

ADULT; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; CROSS PROTECTION; CROSS REACTIONS; HUMANS; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 79551485514     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00402-10     Document Type: Article

References (52)

1. Bermal, N., et al. 2011. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines. Pediatr. Infect. Dis. J. 30:69-72.
2. Bermal, N., et al. 2009. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr. Infect. Dis. J. 28:S89-S96.
3. Bhushan, R., B. F. Anthony, and C. E. Frasch. 1998. Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent. Infect. Immun. 66:5848-5853.
4. Black, S., et al. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19:187-195.
5. Centers for Disease Control and Prevention. 2010. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly. Rep. 59:258-261.
6. Chevallier, B., et al. 2009. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr. Infect. Dis. J. 28:S109-S118.
7. Concepcion, N. F., and C. E. Frasch. 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal- polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8:266-272.
8. Ekström, N., et al. 2005. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect. Immun. 73:369-377.
9. Ekström, N., M. Vakevainen, J. Verho, T. Kilpi, and H. Kayhty. 2007. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect. Immun. 75:1794-1800.
10. Ekström, N., et al. 2008. Establishment of the multiplexed opsonization assay (MOPA4) at KTL, abstr. P3, p. 133. 6th International Symposium on Pneumococci and Pneumococcal Diseases, Reykjavik, Iceland.
11. Eskola, J., et al. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409.
12. Feavers, I., I. Knezevic, M. Powell, and E. Griffiths on behalf of the WHO Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines. 2009. Meeting report. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine 27:3681-3688.
13. Hausdorff, W. P., B. Hoet, and L. Schuerman. 2010. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr. 10:4.
14. Henckaerts, I., N. Durant, D. De Grave, L. Schuerman, and J. Poolman. 2007. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 25:2518-2527.
15. Henckaerts, I., D. Goldblatt, L. Ashton, and J. Poolman. 2006. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin. Vaccine Immunol. 13:356-360.
16. Hicks, L. A., et al. 2007. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196:1346-1354.
17. Jódar, L., et al. 2003. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21:3265-3272.
18. Johnson, S. E., et al. 1999. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J. Infect. Dis. 180:133-140.
19. Katzenellenbogen, E., and H. J. Jennings. 1983. Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 19A (57). Carbohydr Res. 124:235-245.
20. Kieninger, D. M., et al. 2008. Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given with routine vaccines in healthy infants, abstr. G-2117, p. 367. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
21. Kilpi, T., et al. 2003. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharidemeningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37:1155-1164.
22. Klugman, K. P., et al. 2008. Meta-analysis of the efficacy of conjugate vaccines against invasive pneumococcal disease, p. 317-326. In G. R. Siber, K. P. Klugman, and P. H. Mäkelä (ed.), Pneumococcal vaccines: the impact of conjugate vaccine. ASM Press, Washington, DC.
23. Kniskern, P. J., and S. Marburg. 1994. Conjugation: design, chemistry, and analysis, p. 37-69. In R. W. Ellis and D. M. Granoff (ed.), Development and clinical uses of Haemophilus b conjugate vaccines. Marcel Dekker, Inc., New York, NY.
24. Knuf, M., et al. 2009. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr. Infect. Dis. J. 28:S97-S108.
25. Lee, C. J. 2002. Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry. Biologicals 30:97-103.
26. Lee, H., M. H. Nahm, R. Burton, and K. H. Kim. 2009. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin. Vaccine Immunol. 16:376-381.
27. Lees, A., B. L. Nelson, and J. J. Mond. 1996. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14:190-198.
28. Marburg, S., et al. 1986. Biomolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein. J. Am. Chem. Soc. 108:5282-5287.
29. Miyazaki, T., and T. Yadomae. 1971. Polysaccharides of type XIX Pneumococcus. Part II. The type specific polysaccharide and its chemical behaviour. Carbohydr. Res. 16:153-159.
30. Novotny, L. A., et al. 2006. Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae. Vaccine 24:4804-4811.
31. Nurkka, A., et al. 2004. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr. Infect. Dis. J. 23:1008-1014.
32. Pelton, S. I., et al. 2007. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26:468-472.
33. Poolman, J., et al. 2009. Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics. Vaccine 27:3213-3222.
34. Poolman, J. T., et al. 2010. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin. Vaccine Immunol. 17:134-142.
35. Prymula, R., et al. 2008. Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines. Vaccine 26:4563-4570.
36. Prymula, R., et al. 2006. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367:740-748.
37. Prymula, R., and L. Schuerman. 2009. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev. Vaccines 8:1479-1500.
38. Robbins, J. B., et al. 1983. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148:1136-1159.
39. Romero-Steiner, S., et al. 2006. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin. Vaccine Immunol. 13:165-169.
40. Romero-Steiner, S., et al. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol. 4:415-422.
41. Sanderson, C. J., and D. V. Wilson. 1971. A simple method for coupling proteins to insoluble polysaccharides. Immunology 20:1061-1065.
42. Schuerman, L., R. Prymula, V. Chrobok, I. Dieussaert, and J. Poolman. 2007. Kinetics of the immune response following pneumococcal PD conjugate vaccination. Vaccine 25:1953-1961.
43. Schuerman, L., R. Prymula, I. Henckaerts, and J. Poolman. 2007. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media. Vaccine 25:1962-1968.
44. Simell, B., M. Lahdenkari, A. Reunanen, H. Kayhty, and M. Vakevainen. 2008. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin. Vaccine Immunol. 15:1391-1397.
45. Singleton, R. J., et al. 2007. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297:1784-1792.
46. Vesikari, T., et al. 2009. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr. Infect. Dis. J. 28: S66-S76.
47. Vitharsson, G., I. Jonsdottir, S. Jonsson, and H. Valdimarsson. 1994. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J. Infect. Dis. 170:592-599.
48. Whitney, C. G., et al. 2006. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368:1495-1502.
49. World Health Organization. 2008. Meeting report. WHO/Health Canada Consultation on serological criteria for evaluation and licensing of new pneumococcal vaccines, 7 to 8 July 2008, Ottawa, Canada. World Health Organization, Geneva, Switzerland. http://www.who.int/biologicals/publications/ meetings/areas/vaccines/pneumococcal/en/index.html.
50. World Health Organization. 2005. WHO Expert Committee on Biological Standardization. Recommendations for the production and control of pneumococcal conjugate vaccines, p. 64-98. WHO Technical Report Series, no. 927, annex 2. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/trs/ WHO-TRS-927-eng.pdf.
51. Wysocki, J., et al. 2009. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr. Infect. Dis. J. 28:S77-S88.
52. Yu, X., et al. 1999. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J. Infect. Dis. 180:1569-1576.